Animal experiment:

Under pentobarbital anesthesia 26 to 30 g female Swiss-Webster albino mice are injected intratracheally with either 0.05 mL sterile 0.9 % NaCI solution or 150 arthroconidia of Coccidioides imrnitis (strain Silveira) suspended in 0.05 mL of 0.9 % NaCI solution. Treatment of cohorts of ten infected and ten uninfected mice is begun 72 h after inoculation. Daily i.v. injections (tail vein) of 0.1 mL of 5 % glucose solution delivering either 0, 2.5, 5 or 10 mg/kg/dose of Vibunazole are given for 30 days[1].

Vibunazole is a new antifungal azole.

Vibunazole is an antifungal azole. Low concentrations of all three drugs inhibit Coccidioides immitis, strain Silveira, in vitro with a descending order of activity ketoconazole>Vibunazole>BAY 1 9139[1].

The untreated, infected mice lost weight initially and progressively, whereas treated mice gain weight after an initial loss with Vibunazole (all doses), BAY 1 9139 and ketoconazole at 2.5 mg/kg/day. With both Vibunazole and BAY 1 9139, the 5 and 10 mg/kg doses yield serum concentrations exceeding the MICs for the Coccidioides immitis test strain (0.8 and 1.5 μg/mL respectively) for periods in excess of 30 min after injection[1].

[1]. Hoeprich PD, et al. Activity of BAY n 7133 and BAY 1 9139 in vitro and in experimental murine coccidioidomycosis. Eur J Clin Microbiol. 1985 Aug;4(4):400-3.